Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers

Summary

The study is designed as an open-label, randomized, prospective, multicenter, phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with squamous carcinoma of the head and neck (HNSCC)

Timeline

Start

2018-02-02

Primary completion

2021-11-24

Completion

2022-03-23

Outcome

Outcome not reported

Stopped (Enrollment): “A very low recruitment rate made it impossible to reach the recruitment goal wthin an acceptable timeframe.”

Drugs

Indications